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Abbreviations List 
HF                       heart failure                                                        
MI                       myocardial infarction 
LV                       left ventricle 
MR                      mitral regurgitation 
AS                      aortic stenosis 
DCM                    dilated cardiomyopathy 
ACS                     acute coronary syndromes 
TLR4                    toll-like receptor 4 
TLRs                    toll-like receptors 
PRRs                    pattern recognition receptors 
PAMPs                  pathogen associated molecular patterns 
DAMPs                  damage associated molecular patterns 
NF-κB           nuclear factor kappa-light-chain-enhancer of activated B cells 
IFR                     interferon regulatory factor transcription factors  
AngII                   angiotensin II  
TAC                    transverse aortic constriction 
NLRP3          NOD-like receptor family pyrin domain containing protein 3  
TNFR1                    TNF receptor 1  
EMB                   endomyocardial biopsy 
DCs                    dendritic cells 
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mDC                  myeloid dendritic cell 
pDC                  plasmacytoid dendritic cell  
EAM                   autoimmune myocarditis 
CAD                   coronary artery disease 
IVIG                   intravenous immunoglobulin  
CRT                   cardiac resynchronization therapy  
PMVR                 percutaneous mitral valve repair  
RT                    room temperature 
PBMC                 peripheral blood mononuclear cells  
ELISA                 enzyme linked immunosorbent assays  
6MWT                 6-minute walk test  
LVEDD                left ventricular end diastolic diameter  
SSC                   side scatter 
FSC                   forward scatter 
TTE                   transthoracic echocardiograph 
TEE                   transesophageal echocardiography 
IL6                       interleukin-6 
CRP                     C-reactive protein 
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1. Introduction 
1.1 Heart failure 
Heart failure (HF) is considered as the inability of the heart to transport sufficient 
amounts of blood to meet the demands of body at normal filling pressures, finally 
causing a complex and severe disease syndrome. Despite remarkable progress 
in HF therapy regarding both treatment and prevention, the prognosis of patients 
after the first hospital admission is still far from favorable, as it is followed by 
repeated and prolonged hospitalization, and the mortality of HF within 5 years is 
up to 50% (1). Hence, better understanding of the pathophysiological 
mechanisms for HF may accelerate investigations, medical progress and 
therapy for acute and chronic disease. 
1.1.1 Heart failure – a complex and multifaceted disease with increasing 
medical and socioeconomic relevance 
Several underlying causes and involved mechanisms are known for the 
development of HF, which can be classified into categories. Among all, ischemia 
induced by myocardial infarction (MI) or chronic ischemic cardiomyopathy in 
conjunction with further risk factors such as diabetes is the most common cause 
for the progression of left ventricle (LV) dysfunction and HF (2). The predominant 
mechanism is cell death due to lack in tissue supply with oxygen, nutritients as 
well as the removal of noxen generated during the metabolic process. In the 
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similarly prevalent cause for HF in elder patients is caused by chronic 
overstraining of the heart muscle machinery. Most commonly, this mechanical 
stress is derived from arterial hypertension or heart valve dysfunction such as 
mitral regurgitation (MR) or aortic stenosis (AS). These processes result in 
alterations of the heart structure such as ventricular dilation in the case of 
volume overload or hypertrophy in the case of pressure overload or combination 
of both. Commonly such structural alterations are associated with increase in 
cardiac fibrosis, and eventually progress into LV dysfunction (3,4). There are 
also diseases resulting in heart failure, which affect more commonly younger 
patients including autoimmune and microbial infections inflicting damage to the 
heart muscle cells mediated either directly or through innate and adaptive 
immune responses triggered by the infectious agent (5,6). Last but not least, 
genetic diseases such as dilated cardiomyopathy (DCM) are a and rather 
heterogeneous not well understood scenario with heart failure (7). 
The two main different types of HF is chronic HF and acute HF. Chronic HF is 
more common and symptoms appear slowly over time and worsen gradually 
with the underlying mechanisms mentioned above. This situation is of particular 
clinical and therapeutic importance as the majority of patients who are 
diagnosed with chronic HF are those who most likely had HF for some time, and 
presented to hospital only when they became symptomatic. (8) Acute HF can be 
determined as a new symptom or modifies the course of chronic HF and 
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worsens outcome via a combination of potential mechanisms, including 
noncompliance with medication, aggravated hypertension, acute coronary 
syndromes (ACS), arrhythmias and systemic inflammation, (9) which requires 
urgent therapy. Moreover, they are considered as chronic but no longer as acute 
HF once in stabilization after the initial management. (10) 
Recent years, more attentions are focus on the correlation between 
socioeconomic status and disease prognosis. Environmental and social contexts 
play a vital role in health outcomes (11), moreover, in industrial countries, 
socioeconomic imbalance regarding cardiovascular disease present a major and 
ongoing challenge to public health. (12) In HF patients, socioeconomic status 
also displays as predictors of incident HF, for instance, higher rehospitalization, 
incidence and mortality rate is seen in patients under low socioeconomic 
situation. (13,14)  
1.2 Immune response involve in the progress of heart failure 
1.2.1 Relevance of immune mechanisms in heart failure – experimental 
evidence  
Though different mechanisms of HF, there is common to each type with a 
correlation between elevated circulating pro-inflammatory cytokines and adverse 
clinical outcomes. (15) However, different to immune based, immune response 
acts as the secondary response in the other causes. 
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Immune response not only plays as a protective response to organism injuring, 
but also plays an important role in the progress of atherosclerosis (16,17). The 
complicated nature of immune response made it a double-edged sword.       
In ischemic based heart failure, for instance, in the event of MI, inflammatory 
cells infiltrate into the infarct area to initiate the reparative process triggered by 
ischemia and necrotic myocardial cells. In this phase, irreparably damaged or 
dead cells were removed, and infarct was repaired to maintain cardiac integrity 
by scar formation. Therefore, the infiltration of inflammatory cells to the injured 
tissue is considered to be an essential participator for wound healing. The 
sustained inflammation beyond the initial reparative process, however, may later 
extend into the non-infarct remote myocardium, subsequently plays a role in the 
long-term adverse cardiac remodeling. (18,19) In contrast, few studies focus on 
the role of inflammation in the chronic setting of ischemic relevant chronic HF, 
though it plays an important role for cardiac remodeling. To point out, the role of 
toll-like receptor 4 (TLR4) in the progress of chronic HF has been demonstrated 
by recent animal data. (20) TLR4 is a member of toll-like receptors (TLRs) which 
is response for activating the innate immunity. TLRs belong to pattern 
recognition receptors (PRRs), (21) that could identify specific ligands and involve 
in defense against damage associated molecular patterns (DAMPs) or pathogen 
associated molecular patterns (PAMPs) which derive from damaged 
myocardium and  pathogens, respectively. (21) The activated signaling 
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cascades activate nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB), interferon regulatory factor transcription factors (IFR) and activator 
protein 1, that lead to the expression of inflammatory genes. (22) (Figure 1) 
Many stressors, including ischemia, can stimulate cardiomyocytes to release 
DAMPs and activate the above signaling that initiate innate immunity. 
Furthermore, TLR4 upregulation persists in chronic HF, and LV function could be 
improved by the blockade of TLR4 signaling during chronic phase. (20) 
LV overload by mechanical stress can result in myocardial inflammation which is 
triggered by leucocyte infiltration and cardiac pro-inflammatory cytokines release, 
that mostly indicate with two main mouse models, transverse aortic constriction 
(TAC) and angiotensin II (AngII) infusion. Macrophages have been shown to 
mediate hypertension, cardiac remodeling and fibrosis after TAC or AngII 
infusion, and depletion of macrophages resulted in reduced cardiac fibrosis and 
decreased LV hypertrophy. (23,24) The pathological effects of macrophages are 
in part dependent on cytokines release (25), but the role of cytokines in 
regulation of cardiac hypertrophy remains disputable. For example, inhibition of 
IL-6 has been shown to reduce fibrosis and cardiac hypertrophy after AngII 
infusion (26), but it has no effect after TAC (27), moreover, deletion of GP130, 
which is recognized as part of IL-6 receptor complex, surprisingly impairs 
cardiac function leading to dilated cardiomyopathy and increase mortality. (28) 
This indicates the importance of cause and the temporal aspect of disease 
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progression after the different initial insults. Similarly, in chronic HF model of 
mechanical stress by 6 weeks high salt diet, depletion of 
monocytes/macrophages for additional 4 weeks prevents LV remodeling and 
fibrosis, and preserves cardiac function. (24) However, due to the challenge to 
establish MR model with small animals, the role of inflammation for volume 
overload HF remains rare. 
Myocarditis is interpreted as an inflammatory disease of myocardium, which can 
be acute, subacute or chronic, consistently, each type can be inferred as HF with 
LV dysfunction by means of echocardiography. (29) Different to other causes of 
HF, inflammation is involved in this type as the leading response. Viral infection 
is demonstrated to constitute the most prevalent cause of myocarditis among all 
the causes. (29) Onset of viral infection, the myocardial tissue triggers the 
activation of the host defense immune response, which is hallmarked as the 
infiltration of natural killer cells as well as macrophages, subsequently by virus 
specific T lymphocytes. (6) The initial activation of immune response is 
beneficial to the host by attenuating viral proliferation, however, the persistent 
and excessive immune response conveys harmful consequences by contributing 
to the progression of myocarditis and DCM. (30) Besides, special statement that 
damaged cardiomyocytes can lead to the release of intracellular proteins (e.g. 
myosin, actin, troponin, tropomyosin, ß1-adrenoreceptors and muscarinic 
receptors) which serve as self-antigens in order to provoke humoral response 
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result in the generation of auto-antibodies, and this takes an important part in the 
initiation and progression of DCM by aggravating myocardial contractile 
dysfunction. (31) On the other hand, as observed in the cardiac complications 
from some systemic autoimmune disorders, dysregulated humoral response 
itself can directly cause the production of auto-antibodies. The pathogenic 
potential of auto-antibodies has been proved to lead to ventricular dilation and 
dysfunction in animal models of antibodies transfer or by active immunization 
that directly against corresponding epitopes. (32–34)  
Genetics also contribute to the development and progression of DCM. (7) 
Unfortunately, prior studies of transgenic mice model for human familial HF do 
not often explore the role of inflammatory cells and pathways that may potential 
involve in the progress of the disease. Given the association between 
cardiomyocytes fibrotic pathways and immune response (21), it is likely that 
immune response may also modulate the fibrotic progression to genetic 
abnormalities altered cardiomyocyte function that leading to HF development, 
hence, this needs further investigation. 
Furthermore, in recent years, growing evidence come out to support the role of 
gut in the progression of HF. The theory assumed intestinal edema and ischemia 
induced by decreased cardiac output could lead to enhanced intestinal 
permeability, and lead to the entry of lipopolysaccharides into circulation that 
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produced by gram-negative bacteria. (35,36) Moreover, lipopolysaccharides 
serves as type of PAMPs could initiate innate immunity (Figure1) that may 
contribute to the progression of LV dysfunction and HF syndrome. Indeed, 
selective elimination of intestinal aerobic gram-negative bacilli resulted in 
decreased fecal endotoxin concentration, monocyte expression and intracellular 
pro-inflammatory cytokines production in patients with severe HF. (37) This 
provided proof for the gut hypothesis, although this was not successful to display 
significant changes in circulating pro-inflammatory cytokines and endotoxin 
levels. (37) 
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Figure 1. 
 
1.2.2 Relevance of immune mechanisms in heart failure - clinical evidence 
Elevated inflammatory biomarkers, which includes TNF-α, ST2, IL-6, galectin-3 
and pentraxin-3, is a hallmark characteristic for HF. Measurement of biomarkers 
in HF patients and animal studies has convincingly demonstrated the elevation 
of inflammatory cytokines during HF progression, and supporting the “cytokine 
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hypothesis” that inflammation contributes to HF. 
The role of several members in the inflammatory cytokine family has to be 
highlighted. IL-1ß following processing by NOD-like receptor family pyrin domain 
containing protein 3 (NLRP3) inflammasome, involves in bone marrow activation 
and leads to leucocyte production. (38) In addition, murine studies displayed that 
TNF-α promotes inflammation and exerts pro-apoptotic effect via the interaction 
of TNF receptor 1 (TNFR1). (39,40) Alternatively, it has the opposite effect via 
the interaction of TNFR2. (39,40) Further, ST2 belongs to IL-1 cytokine 
superfamily and serves as the receptor of IL-33. In response to mechanical 
stress, cultured myocytes contribute to secrete ST2 and thus, ST2 represent a 
marker for inflammation and mechanical stress. (41) Moreover, galectin-3 
belongs to the lectin family. In response to damaged cells or injured tissue, 
macrophages release galectin-3 that involves in the activation of fibroblast and 
lead to the formation of fibrosis. (42) Furthermore, as mentioned above, function 
of IL-6 in the progress of HF is controversial. In contrast to other cytokines, IL-10 
serves as a major anti-inflammatory cytokine, is proved to reduce macrophage 
accumulation (43) and to reduce inflammatory cytokine expression via 
suppression of NF-κB signaling (44), leading to attenuated LV remodeling. 
In addition, elevated levels of circulating pro-inflammatory cytokines do not only 
associate with disease severity, but also predict the mortality of HF patients. For 
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example, circulating levels of IL-6, TNF, TNFR1 are demonstrated to correlate to 
poorer survival rate of HF patients. (45) 
Clinically, diagnosis of dilated cardiomyopathy (DCM) in HF patients with 
endomyocardial biopsy (EMB) is recommended by present guidelines for both 
diagnosis and treatment of HF (10). In biopsy, myocarditis is indicated as the 
presence of inflammatory cells, fibrosis and tissue necrosis. During acute 
inflammatory disease courses, EMB often shows focal or diffuse lymphocytes 
and/or macrophages infiltration, but rarely eosinophils or giant cells. (46) In 
patients with DCM and chronic HF, up to 30% of EMB is seen with inflammation. 
(46) Whereas compare to acute cases, there is lower number of inflammatory 
cells, and they distribute in a more diffuse manner. In addition, the presence of 
cardiomyocytes hypertrophy, scarring and interstitial fibrosis are the features as 
symbol of lost myocardium. (46)  
1.2.3 Antigen presenting cells and their role in heart failure 
Dendritic cells (DCs) are central to immune activation as their capacity to induce 
naive T cells activation so that to initiate adaptive immune response, (Figure 2) 
as well as their critical role in innate immunity. (47) In the blood circulation, two 
major types of DCs with different functions have been identified, the so called 
myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs). In 
human, mDCs mostly express CD1c and CD11c, which usually are activated by 
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bacterial products and functional for TLR2 and TLR4; pDCs mostly express 
CD303 and CD123, and is respond to viral infections that major activate TLR9. 
(47,48)  
Figure 2. 
 
 17 
In cardiovascular system, DCs do not only present in myocardium, studies by 
Steinman et al. firmly demonstrated that DCs localized in aortic wall and cardiac 
valves as well (49). The turbulent flow by aortic wall and cardiac valves may lead 
DCs to accumulate and capture disease-related pathogens and present to T 
cells (49), accordingly take part in the progress of relevant diseases. Study with 
acute myocardial ischemia mouse model showed that ablation of DCs enhanced 
monocyte/macrophage infiltration and abundance of inflammatory cytokines, led 
to a modulation of LV remodeling and deterioration of LV function. (50) 
Additionally, the role of DCs in autoimmune myocarditis has been recognized (5), 
and its deterioration to DCM is demonstrated in the experimental autoimmune 
myocarditis (EAM) animal model, however, it comes to controversial conclusions. 
For example, one study group demonstrated that DCs are responsible for 
cardiac fibrosis and involved in the progress of HF, (51) but another study group 
suggested that DCs transfected of herpes virus entry mediator could prevent 
EAM in mice. (52)  
In human, significant reduction of circulating DCs precursors has been reported 
in HF patients due to dilated and ischemic cardiomyopathy in all stages of 
disease severity. (53) Study with MI patients displayed the down-regulation of 
circulating DCs cause by their enhanced recruitment into the inflamed 
myocardial tissue (54), however, this seems not to be the case in HF. Decreased 
numbers of DCs were found in a group of DCM patients with heart biopsies, and 
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this phenomenon indicates an unfavorable correlation with outcome in terms of 
HF and tissue fibrosis. (55) To the disappointing results, the authors assumed 
that possibly due to several reasons, for instance, the apoptotic of DCs, 
insufficient vascularization in the area of infected cardiomyocytes, and/or the 
immunomodulation led by regulatory T cells. (55)  
In addition, immune cells take place in the progress of heart valve dysfunction. 
(56) In clinical study, inflammatory response firmly negative correlates with LV 
parameters in valve dysfunction related HF. (57,58) The complex interactions of 
immune cells in heart valve may involve in valvular disease related HF, and DCs 
might be the vital participator, however, with further studies required to clarify the 
crosstalk between DCs and valvular disease related HF.  
1.3 Available treatment options 
Several therapeutic manners have been proposed to test the principle to 
interfere with inflammatory pathway of HF patients, however, the results of large 
studies have produced fairly disappointing results. Stains are widely known 
agents for inhibiting the formation of low density lipoprotein in patients with 
coronary artery disease (CAD), but they also exert anti-inflammatory effects 
through different ways (59,60). Randomized studies with statins to alter 
inflammation in patients of chronic HF did not show benefit, unless in the 
subpopulation presence of dyslipidemia or CAD. (39–40) However, in the 
 19 
retrospective analysis of CORONA study, stain therapy is benefit in patients with 
increased high sensitive-CRP, who showed no difference in previous CAD and 
cholesterol level. (63) Nevertheless, prospective randomized trials have to be 
done to confirm the result. Pro-inflammatory cytokine TNF-α has received much 
attention as a therapeutic target, in view of its central role in the pathophysiology 
of HF. Trails with TNF-α inhibitors infliximab and etanercept did not show benefit 
in HF patients. (64,65) Although trails with pentoxiylline have demonstrated 
improved HF symptoms and LV function, (66–68) as a nonselective 
phosphodiesterase inhibitor, the effects of pentoxiylline to HF maybe beyond its 
anti-inflammatory properties. In addition, intravenous immunoglobulin (IVIG) 
also serves as a potential tool for HF therapy, as its double effect on the cytokine 
network. For example, it is confirmed that IVIG could downregulate the 
pro-inflammatory mediators (such as IL-1), and upregulate the anti-inflammatory 
mediators (such as IL-10). (69) However, the results came conflicting as well 
(69–71). Hence, the overall benefit of anti-inflammatory therapy for HF is still 
unclear.   
In addition, several therapeutic manners have been proposed to indirectly 
interfere the inflammatory pathway of HF patient. Recent years, cardiac 
resynchronization therapy (CRT) represents a valuable option in the treatment 
for a subgroup of HF patients, (10) with this, a biventricular pacemaker is 
implanted to help the heart pump blood through the ventricles to the body more 
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efficiently. As CRT improved cardiac contraction, increase cardiac output 
reduces intestine oedema and correct peripheral circulation that reduce 
inflammatory mediator synthesis, a reduction of inflammatory mediators in CRT 
treated HF patients were found in several trails, which link to reverse cardiac 
remodeling and improve LV function. (72–75) However, there are also several 
studies demonstrated no changes in circulating inflammatory markers (76–78), 
which might cause by statistical errors from a small study population or 
heterogeneity between patient groups.  
Although many studies and clinical trials regarding treatment target on 
inflammation in HF, the results remain controversial, which might due to the 
complex nature of the immune cells, inflammatory cytokines as well as the 
mechanisms of different HF subtypes. As we gain a greater understanding of 
immune mediator and their role in cardiac injure and repair, but from the 
mentioned above, our knowledge is still superficial to date. Hence, more studies 
have to be carried out, especially regarding chronic HF as it represents most of 
the cases in clinical HF patients, and inflammation in genetic as well as valve 
dysfunction related HF, which is scarce studies before. Also a better 
understanding of the functional implication with the immune mediators in HF 
may help focus new therapies target in the future.  
1.4 Aims of study 
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There is emerging evidence that immune response plays a vital role in the 
progress of LV remodeling, however, data for patients of volume overload HF 
are not available, so far. Percutaneous edge-to-edge mitral valve repair (PMVR) 
for patients of MR with MitraClip® system represents a good human model to 
study volume stress to the heart before and after treatment, because compare to 
the on pump surgery, it avoids the bias caused by the artificial circulation. Since 
DCs mediate as center of any immune response, we investigated the number 
and phenotype of DCs precursors in patients underwent PMVR with MR related 
volume overload HF. 
The aims of the thesis were the following: 
To show the number change of both mDCs and pDCs in circulating before 
PMVR and during follow up. 
To show the altered phenotype of both mDCs and pDCs in circulating before 
PMVR and during follow up. 
To assess a possible correlation between DCs and clinical parameters. 
To investigate an influence of DCs numbers with systemic inflammation status. 
To investigate an influence of DCs changing on functional recovery.  
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2. Materials and methods 
2.1 Study population  
The study population consisted of 125 patients with grade 3 or 4 MR, who 
underwent PMVR at the University Hospital, Department for Cardiology and 
Cardiovascular Medicine, University of Tuebingen. We included 80 patients and 
re-evaluated them at 6-month follow-up. 45 patients were lost to follow up, as 35 
patients passed away and 10 patients opted to withdraw from the study. Venous 
blood samples of 11 healthy donors served as controls. All the patients were 
informed and agreed before the blood taken, and the consent forms were 
obtained from all the subjects. Heart failure patients had to be on optimal 
medical treatment for at least 3 months prior to MitraClip® treatment according to 
current guidelines. 
2.2 Identification of DC precursors by flow cytometry  
All blood samples were collected using Lithium-Heparin blood collection tubes 
(Sarstedt, Nuembrecht, Germany) and analyzed immediately after sample 
submission. Dates of analysis were the day of PMVR and at a median of 5.8 
months (4-10.2 months) after PMVR. The used fluorescence conjugated mouse 
anti-human antibodies are as following: CD1c (BDCA-1)-PE, CD303 
(BDCA-2)-PE (both from Miltenyi Biotec, Germany), CD14-PerCPCy5.5, 
CD19-PerCPCy5.5, CD11a-FITC, CD40-FITC, CD86-APC, HLA-DR-APC (all 
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from BioLegend, San Diego, USA). FACS analysis was performed according to 
the Blood Dendritic Cell Enumeration Kit protocol from Miltenyi-Biotec. In brief, 
300µl of whole blood was added to each sample and erythrocytes were lysed by 
ammonium chloride (Stemcell, Cologne, Germany). Platelets were removed by 
two centrifugation steps at 300g each. The samples were incubated with human 
Fc-Receptor Block (Miltenyi Biotec, Germany) for 10 min on ice, then incubated 
with fluorescence conjugated mAb or isotype control murine IgG (Miltenyi Biotec, 
Germany) for 10 min at room temperature (RT). After staining, cells were 
incubated in 1% paraformaldehyde for fixation and tested by flow cytometry 
(FACS-Calibur flow cytometer Becton-Dickinson, Heidelberg, Germany) within 
24 hours. Data analysis was carried out with FlowJo software (Tree Star, 
Ashland, USA). As DC precursors represent a low population (about 1% of 
peripheral blood mononuclear cells (PBMCs)), in order to detect the numbers of 
circulating mDC and pDC precursors more accurately, a special gate strategy 
was designed (Figure 3.) according to previous study (54). To avoid the 
methodical bias caused by the small cell population, we analyzed the blood 
sample from each patient for three times, and mDC and pDC numbers were 
described as the mean value of the resulting data. The percentage of CD1c 
labeled cells (gated in R3a) and CD303 labeled cells (gated in R3b) to PBMCs 
(gated in R1) were determined as the relative numbers of mDC and pDC 
precursors, respectively. The absolute numbers of mDC and pDC precursors 
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were described as cells per microliter (cells/µl), which is based on the relative 
DCs numbers in relation to leucocytes count, and the leucocytes number was 
measured with an automated cell counter (Sysmex, Norderstedt, Germany). 
Figure 3.  
 
Figure 3. Gate strategy for discrimination of circulating mDC and pDC precursors by flow 
cytometry. Region R1= acquiring of peripheral blood mononuclear cells (PBMCs) according to 
the forward scatter (FSC) and side scatter (SSC). Region R2 = exclusion of granulocytes by SSC, 
monocytes by CD14 staining, B lymphocytes by CD19 staining. Region R3a and R3b = 
identification of circulating mDC and pDC precursors according to their specific CD1c and 
CD303 staining, respectively. 
2.3 Analysis of DCs surface markers with Imaging Flow Cytometer 
As the small population of DCs in circulating, it is a challenge to isolate mDCs 
and pDCs from peripheral blood. We determined the surface expression of 
   R3a
 
  
   R3b 
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co-stimulatory molecules CD86 and HLA-DR, adhesion molecules CD11a on 
single mDCs or pDCs with ImageStream®X Mark II Imaging Flow Cytometer 
(Merck Millipore, Germany). Blood samples were collected from 5 patients using 
citrate blood collection tubes (Sarstedt, Nuembrecht, Germany) and after 
submission samples were analyzed immediately. The used fluorescence 
conjugated mouse anti-human antibodies are as following: CD303 (BDCA-2)-PE 
(Miltenyi Biotec, Germany), CD1c (BDCA-1)-PE/Cy7, CD11a-PerCP, 
CD86-Brilliant Violet 421, and HLA-DR-Brilliant Violet 605 (all from BioLegend, 
San Diego, USA). DCs purification was carried out according to the Blood 
Dendritic Cell Isolation Kit II of Miltenyi-Biotec (Miltenyi Biotec, Germany). In 
brief, PBMCs were isolated using density gradient centrifugation with 
Ficoll-Paque (Sigma, Germany). Platelets were removed by two centrifugation 
steps at 150g each. Total human DCs were purified by two steps separation 
using MACS system. For that, PBMCs were incubated with cocktail of 
biotin-conjugated monoclonal anti-human CD1c antibody, and microbeads 
conjugated monoclonal anti-human CD14 and CD19 antibodies. During the first 
negative selection, B cells and monocytes were bound by their specific 
antibodies coupled to beads. Therefore, DCs enriched cell population flow 
through the column in the magnetic field. In the subsequent step, the flow 
through population was incubated with microbeads conjugated DCs enrichment 
cocktail. In this positive selection step, the magnetic beads retain the DCs in the 
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column, and DCs were eluted from the column outside of the magnetic field. For 
the detection of surface markers, pre-purified DCs pellets containing 2x105 cells 
were resuspended in 1.5ml Eppendorf tubes with FACS buffer (PBS, 5%BSA, 
0.1%NaN3 sodium azide). After washing steps, the cell pellets were incubated 
with human Fc-Receptor Block (Miltenyi Biotec, Germany) for 10 min on ice, 
then incubated with a mixture of fluorescence conjugated antibodies for 10min at 
RT. After staining, cells were incubated with 1% paraformaldehyde for fixation. 
After washing steps, cells were resuspended in PBS and analyzed with imaging 
flow cytometer within 24 hours.   
2.4 Multiplex Enzyme linked immunosorbent assays (ELISA)  
CRP, IL-6, ST2, TNF-α and IL-10 levels were analyzed in a subgroup of patients 
by commercially available ELISA kits (eBioscience, R&D) according to the 
manufacturers’ protocol. For analysis of blood samples, Lithium-Heparin or 
EDTA plasma probes were initially centrifuged for 10min at 1250g within 30 
minutes of collection. Samples were directly put in -80°C refrigerator and stored 
until analysis.  
2.5 Clinical parameters  
To have an objective measure of functional capacity, patients underwent the 
6-minute walk test (6MWT) before PMVR and at follow up, monitored by the 
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same investigator according to the recommendation of the American Thoracic 
Society. (79) Transthoracic echocardiography （TTE） and transesophageal 
echocardiography (TEE) were performed in all patients within 30 days prior to 
PMVR and at follow up using a Philips CX 50 and iE 33 machine (Philips 
HealthCare, Hamburg, Germany). The severity of MR at baseline was 
determined according to the current European Association of Echocardiography 
guidelines. (80) 
2.6 Statistical analysis   
Statistical analysis was performed with GraphPad Prism 6 software (GraphPad, 
San Diego, USA), including descriptive, comparative and relational analysis. 
Continuous variables are presented as means ± standard error of the mean 
(SEM), categorical variables are shown with relative or absolute numbers. For 
comparisons between groups, Mann-Whitney rank test was used for statistical 
comparison. For correlation analysis, Spearman rank test was performed to test 
the relativity. The 2-tailed p value< 0.05 was considered statistically significant 
for both tests.  
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3. Results 
3.1 Baseline Characteristics 
A total of 80 patients undergoing PMVR was finally enrolled. The mean age was 
75.2 years (range, 38 to 89). Median follow up was 5.8 months (range: 4 to 10). 
Baseline characteristics of all patients are depicted in Table 1. 
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Table 1 
Baseline patient characteristics (n=80) 
Age  75.2 (38 to 89) 
Male gender 47 (58.8%) 
Coronary heart disease 57 (71.3%) 
Atrial fibrillation 49 (61.3%) 
Hypertension  54 (67.5%) 
Smoker 14 (17.5%) 
Hyperlipoproteinemia 37 (46.3%)  
Diabetes 24 (30.0%) 
NYHA-class 3-4 76 (95.0%) 
Renal insufficiency 33 (41.3%) 
LV Function   
≤35% 39 (48.8%) 
36-50%   20 (25.0%) 
>50%  21 (26.2%) 
Regurgitation etiology  
Functional 41 (51.3%) 
Degenerative 27 (33.7%) 
Mixed 12 (15.0%) 
Betablockers 71 (88.8%) 
Aldosteronantagonist 42 (52.5%) 
ACE-inhibitors/Sartane 71 (88.8%) 
Diuretics  74 (92.5%) 
Digitalis 6 (7.5%) 
Calcium-Antagonists 11 (13.8%) 
Anticoagulation 52 (65.0%) 
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3.2 FACS analysis of circulating DCs 
Circulating mDC and pDC precursors were discriminated according to their 
specific surface markers CD1c and CD303, respectively. B cells and monocytes 
which also express DC markers were prior excluded by their surface markers 
CD19 and CD14 (Figure 3). Circulating mDC numbers ranged from 0.01% to 0.3% 
of leukocyte counts and pDC numbers from 0.01% to 0.4% of leukocyte counts 
in our FACS analysis, respectively. These values are in the range as previous 
studies described. (53,54) When comparing with the patients who underwent 
PMVR, a reduced number of mDCs was observed in patients before PMVR as 
compared to controls. (0.11 vs. 0.19%, P<0.001) (Figure 4A). Such a reduction 
was not only seen in relative, but also in absolute numbers (6.87/µl vs. 10.38/µl, 
P=0.003) (Figure 4B), hence excluding a possible dilution effect. Interestingly, 
the level of circulating mDC precursors increased significantly 6 months after 
treatment and returned to values similar to the healthy control group (Figure 4B), 
with a similar tendency in relative numbers (Figure 4A). Similar to the findings for 
mDCs, relative pDCs were significantly decreased in patients with MR compared 
to the healthy control subjects (0.07 vs. 0.1%, P<0.05) (Figure 4C). After 
treatment, the number of circulating pDC precursors significantly increased (0.07% 
vs. 0.1%, P=0.0002 for relative number; 4.86/µl vs. 6.56/µl, P=0.0011 for 
absolute number) (Figure 4C, D). 
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Figure 4. 
 
Figure 4. Relative and absolute numbers of circulating mDC and pDC precursors in control group 
(n=11), patients with MR before PMVR (pre PMVR, n=80) and at 6 months follow up (follow up, 
n=80). Circulating mDC precursors are shown as a percentage of leucocytes (A) and as cells per 
microliter (cells/μl) (B). Circulating pDC precursors are shown in (C, D). Graphs depict median 
(line in the box), 25th (upper boundary of box) and 75th (lower boundary of box) percentile. 
*P<0.05. 
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3.3 Analysis for phenotype of DC precursors 
To phenotype DCs, we detected the expression of adhesion molecule CD11a, 
co-stimulatory molecules HLA-DR (MHC class II) and CD86 with imaging flow 
cytometer (Figure 5). A high amount of CD11a and HLA-DR was found 
constitutively expressed on both mDC and pDC precursors, which is known in 
the prior studies (48,81). By FACS, we detected the adhesion molecule CD11a, 
co-stimulatory molecules CD40, CD86 and HLA-DR on DC precursors. We 
detected no significant change in co-stimulatory molecules for both mDC and 
pDC precursors before and after PMVR, although there is a significant increased 
expression of CD40 and decreased expression of HLA-DR on mDC precursors 
in patients compare to control subjects. (Figure 6) However, we observed a 
significantly increased expression of adhesion molecule CD11a on mDC 
precursors before PMVR compared to control subjects, (Figure 7) whereas no 
significant difference for pDC surface expression of CD11a was detected. 
Interestingly, at follow up of 6 months after PMVR, both mDC and pDC surface 
expression of CD11a were significantly decreased (MFI: 135 vs. 105, P<0.0001 
for mDC; 97 vs. 72, P=0.002 for pDC). Thus, the levels and the phenotype of 
circulating DC precursors change after PMVR. 
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Figure 5. 
 
 
 
Figure 5. (A) Screen capture of gate strategy for analysis of DCs. Representative scatter plots of 
cells labeled with CD1c (gated in yellow) and CD303 (gated in blue). In the image gallery of 
single cells, the yellow color represents CD1c labelled cells, blue color represents CD303 
labelled cells, pink represents CD11a, purple represents CD86 and orange represents HLA-DR. 
(B1) and (C1) represent the single staining for mDCs and pDCs, respectively. (B2) and (C2) 
represent the overlay of surface markers with mDCs and pDCs, respectively. Scale bar = 7µm. 
A
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Figure 6. 
 
Figure 6. Circulating mDC and pDC precursors surface expression of co-stimulatory molecules. 
Levels of CD40 (A), CD86 (B) and HLA-DR (C) shown as mean fluorescence intensity (MFI) 
were analyzed by flow cytometry. control, n=11; pre PMVR, n=80; follow up, n=80. Data is shown 
as mean ± SEM.  
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Figure 7. 
 
 
Figure 7. Expression of homing and adhesion molecule CD11a on mDC (A) and pDC (B) 
precursors. Expression of CD11a is presented as mean fluorescence intensity (MFI). control, 
n=11; pre PMVR, n=80; follow up, n=80. Data is shown as mean ± SEM. *P<0.05 
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3.4 Correlations of circulating mDCs with CD40 and HLA-DR 
As the significant changing of CD40 and HLA-DR on mDCs between control 
group and patients, we also examined the correlations between mDCs and 
CD40, HLA-DR expression in patients. We found that the up regulation of CD40 
in patients was inverse correlated with circulating mDCs , and the down 
regulation of HLA-DR in patients was positive correlated with circulating mDCs 
(Figure 8). 
 
Figure 8. 
      
 
 
Figure 8. Association of mDC precursors with co-stimulatory molecules. Significant inverse 
correlation between the relative circulating mDC precursors numbers and their surface 
expression of CD40 (A), n=80. Significant positive correlation between the relative circulating 
mDC precursors numbers and their surface expression of HLA-DR (B), n=80. 
 
 
  A                                  B    
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3.5 Improvement of clinical parameters 
In order to identify a possible improvement of clinical parameters for HF, we 
measured the typical parameters of LV remodeling and HF, such as left 
ventricular end diastolic diameter (LVEDD), distance of 6-minute walk test 
(6MWT), as well as heart failure biomarkers, such as pro-inflammatory markers 
CRP, IL-6, ST2, TNF-α and anti-inflammatory marker IL-10, before PMVR and at 
6 month follow up. There is significant changing of LVEDD, 6MWT, IL-6 and CRP, 
see Figure 9, which parallel with the changing of circulating DCs.  
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Figure 9.  
 
 
Figure 9. Left ventricular end diastolic diameter (LVEDD, A) as a parameter for volume overload 
was determined, n=55. Distance of 6-minute walk test (6MWT, B), n=46. Plasma levels of 
interleukin-6 (IL6, C), n=70, and C-reactive protein (CRP, D), n=75 were analyzed. Data is shown 
as mean ± SEM. *P<0.05  
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3.6 Correlation analysis of circulating mDCs and heart failure parameters 
To confirm the relation of DCs to heart failure parameters, we further conducted 
correlation statistics between the changing of DCs and the changing of above 
clinical heart failure parameters. The recovery of mDCs correlated well with 
6MWT, as well as inversely correlated with IL-6 and CRP. (Figure 10) 
In contrast to the above findings for mDCs, pDC analyses did not yield any 
correlates among groups. (Figure 11) 
 
Figure10. 
  
      
 
Figure 10. Association of mDC precursors with markers of heart failure parameters. Significant 
positive correlation between the increased relative circulating mDC precursors numbers and the 
improvement in 6-minute walk test (6MWT) distance (A). Significant inverse correlation between 
the change in relative circulating mDC precursors numbers and change of plasma interleukin-6 
(IL6, B) and C-reactive protein (CRP, C) levels.  
 
 
 A                      B               C 
 40 
Figure 11. 
 
 
 
Figure 11. No correlation was observed between the change in the relative number of circulating 
pDC precursors and the improved functional capacity of HF patients as assessed with the 
6-minute walk test (6MWT) distance (A), with plasma levels of interleukin-6 (IL6, B) or with 
C-reactive protein (CRP, C).  
 
 
 
 
 
 
 
 
 A                      B               C 
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4. Discussion 
In our study we were able to show that i) the numbers of circulating mDC and 
pDC precursors are reduced in MR related HF patients, and PMVR treatment 
increased their levels at a follow up after 6 months, furthermore, ii) the reduction 
of mDCs in patients correlates with the expression of co-stimulatory molecules 
CD40 and HLA-DR. iii) After PMVR, the phenotype of circulating DCs changed, 
which showed for example decreased expression of the homing molecule 
CD11a and that iiii) change of mDC precursors correlated with improvement of 
clinical parameters of HF and inversely correlated with markers of an 
inflammatory response.  
Two major different types of DCs and their migratory route have been described 
in human. (48,82) Both types of DCs appear to be in transit in the peripheral 
circulation as precursor cells before they migrate into peripheral tissues. (83) 
Significant alteration of circulating DC precursors has been reported in several 
immune-mediate diseases, (54,84,85) and it is assumed that their reduced 
presence is mediated by enhanced recruitment into inflamed tissue (54). In the 
cardiovascular system in mice, it was recently demonstrated that DCs are 
present within the aortic wall and heart valves, and the localization of DCs is 
mainly in areas with turbulent flow. (49). In MR patients, volume overload causes 
disturbed flow at various areas of the heart tissue including the heart valves, 
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predominantly during the systolic period. (86) 
In the present study, we explored whether any change of circulating DC 
precursors might be associated with an immune activation in advanced heart 
failure. We found that the number of peripheral circulating mDC precursors is 
significantly decreased in patients with MR related heart failure compared with 
healthy control subjects. Additionally, the treatment of PMVR and, thus, 
reduction of volume overload resulted in increased number of circulating mDC 
and pDC precursors at 6 month follow up, similar to levels of the healthy control 
group. More interestingly, we observed the decreased number of mDCs in 
patients before treatment is associated with the change of phenotypes of CD40 
and HLA-DR. 
Elevated inflammatory biomarkers, which includes TNF-α, ST2, IL-6, CRP, is a 
hallmark characteristic for HF. (21) Measurement of biomarkers in HF patients 
and animal studies have convincingly demonstrated the elevation of 
inflammatory cytokines during HF progression. (21) Previous clinical intervention 
studies have tested the principle to interfere with inflammatory pathways. 
(65,69,71) The achieved properties in patients with HF, however, have produced 
fairly disappointing results. (21,62,65,71) This outcome may reflect the 
complexity of HF pathophysiology with different underlying disorders from 
inflammatory cardiomyopathy to ischemic heart disease. We assessed instead 
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patients with congestive HF caused by MR featuring volume overload as a 
predominant mechanism of disease. Future studies will have to scrutinize the 
number of circulating DC precursors, their phenotype and their correlation with 
clinical parameters, in other settings of heart failure as well. In our patient 
collective, we furthermore observed a significant reduction of classical 
pro-inflammatory cytokines IL-6 and CRP in MR patients 6 months after PMVR 
treatment. The increased levels of circulating mDC precursors correlated with 
the change of plasma IL-6 and CRP levels, thus reflecting a potential crosstalk 
between the presence and phenotype of these immune cells to inflammatory 
processes in HF patients, rather than it being an isolated phenomenon. Further 
studies, however, will have to test this hypothesis more profoundly. Interestingly, 
mDC precursors showed a significant correlation with the functional capacity in 
heart failure patients. In contrast, we did not find any correlation with circulating 
pDC precursors suggesting cell specificity for this observation. In oder to further 
challenge and characterize the involvement of circulating DC precursors and 
their phenotype as a decisive factor or a potential biomarker in patients with HF 
caused by volume overload, future basic and clinical studies are warranted.  
In conclusion, we demonstrate to our knowledge for the first time an effect of 
interventional treatment for MR featuring cardiac volume stress on levels of 
circulating DC precursors and their phenotype, which was associated with 
increase in functional capacity and reduction of inflammatory markers. Thus, our 
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results point to a previously unattended intersection point between volume 
overload and a cellular immune response. 
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5. Summary 
Aim: Immune mechanisms and inflammation contribute to the pathophysiology 
of heart failure (HF) in different ways. As the center of immune response, 
dendritic cells (DCs) play an important role in LV remodeling after myocardial 
ischemia and myocarditis, however, the role of dendritic cells in non-ischemic HF 
with volume overload has not be addressed, so far. Here, we investigated the 
number and phenotype of circulating DC precursors in a patient collective 
undergoing percutaneous mitral valve repair (PMVR) of mitral regurgitation to 
uncover the potential crosstalk of volume overload HF with immune regulation. 
Methods: Using flow cytometry, we determined the numbers of circulating 
myeloid DCs (mDCs), plasmacytoid DCs (pDCs) and their surface expression of 
co-stimulatory molecules CD40, CD86, HLA-DR, as well as adhesion molecule 
CD11a in healthy control subjects (n=11) and MR patients at the time of PMVR 
(n=125) and at a median follow-up (n=80) of 5.8 (4 to 10) months. Levels of 
plasma inflammatory cytokines and change in left ventricular end-diastolic 
diameter (LVEDD) were assessed, and a 6-minute walk test was carried out 
prior to PMVR and during follow-up. Results: Compared to controls (mDC 
10.38/µl and pDC 5.44/µl, respectively), patients with MR had significantly 
decreased numbers of circulating mDC precursors (6.87/µl, P<0.01), whereas 
there was no significant difference regarding pDC precursors (4.86/µl). While a 
significant up-regulation of mDC surface expression of CD11a (mean 
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fluorescence intensity (MFI) 160, P<0.05) was detected compared to healthy 
controls (MFI: 130), no significant differences for CD40, CD86 and HLA-DR 
were found. During follow-up, PMVR treatment restored reduction of circulating 
mDC precursors (8.93/µl, P<0.001). Furthermore, we observed an increase in 
circulating pDC precursors (6.56/µl, P<0.01). Simultaneously, surface 
expression of CD11a on circulating mDC and pDC significantly decreased after 
PMVR. The increased numbers of circulating DC precursors after PMVR was 
paralleled by a reduction of CRP, IL6 levels, decreased LVEDD and an 
improvement of 6-minute walk test distance. Interestingly, the change in mDC 
levels showed a positive correlation with 6-minute walk test distance and an 
inverse correlation with inflammatory markers CRP and IL-6. Conclusions: Our 
findings suggest that the change of circulating DC precursors may be involved in 
the pathophysiology of MR relevant HF.  
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6. Zusammenfassung 
Ziel: Immune Mechanismen und Entzündungen werden vorgeschlagen, um die 
Pathophysiologie der Herzinsuffizienz (HF) auf unterschiedliche Weise zu 
beeinflussen. Als Zentrum der Immunantwort spielen auch dendritische Zellen 
(DCs) eine wichtige Rolle bei der LV-Remodellierung nach Myokardischämie 
und Myokarditis, jedoch ist die Rolle der dendritischen Zellen bei 
nicht-ischämischen HF mit Volumenüberlastung bisher nicht angesprochen 
worden. Hier untersuchten wir die Anzahl und den Phänotyp zirkulierender 
DC-Vorstufen in einem Patientenkollektiv, das einer perkutanen 
Mitralklappenreparatur (PMVR) der Mitralinsuffizienz unterzogen wurde, um das 
mögliche Übersprechen der Volumenüberlastung HF mit Immunregulation 
aufzudecken. Methoden: Mit Hilfe der Durchflusszytometrie ermittelten wir die 
Anzahl der zirkulierenden myeloiden DCs (mDC), der Plasmacytoid-DCs (pDC) 
und ihrer Oberflächenexpression der co-stimulatorischen Moleküle CD40, CD86, 
HLA-DR sowie des Adhäsionsmoleküls CD11a bei gesunden Kontrollpersonen 
(N = 11) und MR-Patienten zum Zeitpunkt der PMVR (n = 125) und bei einem 
medianen Follow-up (N =80) von 5,8 (Bereich: 4 bis 10) Monate. Ebenen der 
Plasma-entzündlichen Zytokine, Veränderung des linksventrikulären 
enddiastolischen Durchmessers (LVEDD) wurden beurteilt und ein 
6-Minuten-Gehtest wurde vor dem PMVR und während des Follow-up 
durchgeführt. Ergebnisse: Im Vergleich zu den Kontrollproben (mDC 10,38/μl 
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bzw. pDC 5,44/μl) zeigten die Patienten mit MR signifikant verminderte Anzahl 
an zirkulierenden mDC-Vorläufern (6,87/μl, P <0,01) War kein signifikanter 
Unterschied bezüglich der pDC-Vorläufer (4,86/ul). Während eine signifikante 
Erhöhung der mDC-Oberflächenexpression von CD11a (mittlere 
Fluoreszenzintensität (MFI) 160, P <0,05) im Vergleich zu gesunden Kontrollen 
(MFI: 130) festgestellt wurde, wurden keine signifikanten Unterschiede für CD40, 
CD86 und HLA-DR gefunden. Während der Nachuntersuchung führte die 
PMVR-Behandlung zu einer Reduktion von zirkulierenden mDC-Vorläufern 
(8,93/μl, P<0,001). Darüber hinaus beobachteten wir eine Zunahme der 
zirkulierenden pDC-Vorstufen (6,56/μl, P <0,01). Gleichzeitig verringerte sich die 
Oberflächenexpression von CD11a beim Zirkulieren von mDC und pDC nach 
PMVR signifikant. Die erhöhte Anzahl von zirkulierenden DC-Vorläufern nach 
PMVR wurde durch eine Reduktion von CRP, IL6 Niveaus, vermindertem 
LVEDD und einer Verbesserung der 6-minütigen Spaziergangsteststrecke 
verglichen. Interessanterweise zeigte die Veränderung der mDC-Spiegel eine 
positive Korrelation mit einer 6-minütigen Wanderteststrecke und einer inversen 
Korrelation mit den entzündlichen Markern CRP und IL-6. Schlussfolgerungen: 
Unsere Ergebnisse deuten darauf hin, dass die Veränderung der zirkulierenden 
DC Vorläufer in der Pathophysiologie der MR relevant HF beteiligt sein kann. 
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